{"schema_version":"secwatch.filing_event.v1","accession":"0000939767-24-000054","form_type":"8-K","ticker":"EXEL","cik":"0000939767","company_name":"EXELIXIS, INC.","filed_at":"2024-04-30T23:59:59+00:00","discovered_at":"2026-05-14T18:03:22.561021+00:00","generated_at":"2026-06-03T05:17:00.052032+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Exelixis Q1: revenue $425M, GAAP EPS $0.12, non-GAAP $0.17, restructuring $32.8M","bullets":["Total revenues $425.2M, up 4% YoY from $408.8M; cabozantinib U.S. net product revenues $378.5M, up from $363.4M.","GAAP net income $37.3M ($0.12 diluted EPS); non-GAAP net income $52.0M ($0.17 diluted EPS) vs $52.8M ($0.16) in Q1 2023.","Recorded $32.8M restructuring expenses (severance, asset impairment, contract termination) from January 2024 restructuring.","Pipeline: three ongoing pivotal trials for zanzalintinib; phase 1 studies for XB002 (ADC) and XL309 (USP1 inhibitor); up to three IND filings expected in 2024.","Ongoing cabozantinib IP litigation with MSN Pharmaceuticals; second bench trial ruling expected spring 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0000939767-24-000054","json":"https://secwatch.observer/filing/0000939767-24-000054.json","markdown":"https://secwatch.observer/filing/0000939767-24-000054.md","text":"https://secwatch.observer/filing/0000939767-24-000054.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/939767/000093976724000054/0000939767-24-000054-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/939767/000093976724000054/exel-20240430.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-03T05:17:00.052032+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"ffcd5ccec8ed53c279076ba970d24427822834f6","claim":"EXELIXIS, INC. reported First Quarter 2024 results: revenue $425 million, EPS $0.12.","evidence_excerpt":"Exelixis Announces First Quarter 2024 Financial Results and Provides Corporate Update - Total Revenues of $425 million, Cabozantinib Franchise U.S. Net Product Revenues of $379 million - - Restructuring Expenses of $32.8 million Recorded - - GAAP Diluted EPS of $0.12, Non-GAAP Diluted EPS of $0.17 -","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/939767/000093976724000054/0000939767-24-000054-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"First Quarter 2024"},{"label":"Revenue","value":"$425 million"},{"label":"EPS","value":"$0.12"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}